First-line sorafenib vs capecitabine in patients with advanced liver cancer
Phase of Trial: Phase II
Latest Information Update: 29 Oct 2012
Price : $35 *
At a glance
- Drugs Capecitabine (Primary) ; Sorafenib
- Indications Liver cancer
- Focus Therapeutic Use
- 29 Oct 2012 New trial record
- 02 Oct 2012 Results presented at the 37th Congress of the European Society for Medical Oncology.
- 28 Sep 2012 Primary endpoint 'Progression-free-survival-duration' has not been met.